Business Wire

NY-THIRD-AVENUE-MGMT

26.2.2024 12:01:30 CET | Business Wire | Press release

Share
Third Avenue Launches Global Value UCITS For Non-U.S. Investors

Third Avenue Management LLC (“Third Avenue”), a New York City-based investment adviser and leading value investing firm, is pleased to announce the upcoming launch of the Third Avenue Global Value Fund (ISIN: IE000K2CIQ63)1. The Fund will run in parallel with Third Avenue’s flagship global value strategy and employ Third Avenue’s unique fundamental, bottom-up, value investing philosophy in publicly traded securities globally.

The global value strategy has been managed for more than three decades and, since its inception in 1990, has provided investors with attractive long-term returns. The Fund will be structured as a sub-fund of Ireland-domiciled UCITS, Gemini Investment Funds (Ireland) Plc2, and is the second UCITS fund offering from Third Avenue along with its highly regarded Third Avenue Real Estate Value Fund (ISIN: IE00B6WFK718).

“We are thrilled to offer the Third Avenue Global Value Fund to qualified non-US investors,” said Portfolio Manager Matthew Fine. “For more than three decades, Third Avenue has delivered attractive results using a unique balance sheet-focused, price-conscious, fundamental value philosophy, an approach that is arguably more uncommon today than at any point in many decades. We also believe it to be an excellent time to broaden the availability of our strategy to a wider investor base, given the rapidly growing investor interest in value strategies as an alternative to growth-oriented and index-based strategies.”

Third Avenue has partnered with Capital Strategies Partners, an independent third-party marketer headquartered in Madrid with a global presence that specializes in identifying talented managers for local distribution.

“We are excited about our partnership with Capital Strategies,” said Erik Kleinbeck, Managing Director and Head of Business Development at Third Avenue. “This relationship allows Third Avenue to focus on our core equity portfolio management expertise while leveraging the reach and scale of Capital Strategies’ 20 years of experience in client acquisition and retention in the asset management industry.”

“We are delighted to extend a warm welcome to Third Avenue as a valued Investment Manager. By launching the Global Value Fund as a UCITS vehicle, we hold firm in our confidence that Third Avenue’s resilient and proven methodology and track record will effectively cater to the needs of our investor base, spanning both institutional and wholesale segments,” said Daniel Rubio, Founder & CEO of Capital Strategies Partners.

“As a business that values our partnerships with Fund Managers in building strong investment propositions for investors, we at GemCap look forward to continuing our collaboration with Third Avenue to launch the Third Avenue Global Value Fund and work with Capital Strategies Partners to deliver this strategy to the broader UCITS fund investor community,” said Stuart Alexander, Director of Gemini Capital Management3.

About Third Avenue Management 
Third Avenue Management LLC is a New York City-based investment adviser founded in 1986 by legendary investor Martin J. Whitman. For more than 35 years, the Firm has consistently pursued a value approach to investing by focusing on the company’s balance sheet, the value of its underlying assets, the discounted price of its securities, and the ability of the enterprise to increase its corporate net worth over time. Today, the Firm is partnered with AMG (NYSE: AMG) and has more than $1.4 billion in assets under management across its five core strategies – Global Value (Nasdaq: TAVFX), U.S. Small-Cap Value (Nasdaq: TASCX), Global Real Estate (Nasdaq: TAREX), International Real Estate (Nasdaq: REIFX), and International Value – which are available to investors through Mutual Funds, UCITS, Separate Accounts, and Sub-Advisory arrangements. For more information visit Third Avenue at www.thirdave.com.

_________________________
1
The launch of the Third Avenue Global Value Fund is subject to final regulatory approval of the Fund, expected around March 1, 2024 
2 Gemini Investment Funds (Ireland) Plc is authorised by the Central Bank of Ireland (C67292) 
3 Gemini Capital Management (Ireland) Ltd is authorised by the Central Bank of Ireland (C155302)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226950474/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye